Advertisement
Canada markets close in 5 hours 28 minutes
  • S&P/TSX

    21,876.85
    +82.95 (+0.38%)
     
  • S&P 500

    5,485.83
    +7.93 (+0.14%)
     
  • DOW

    39,183.79
    +55.99 (+0.14%)
     
  • CAD/USD

    0.7304
    +0.0005 (+0.07%)
     
  • CRUDE OIL

    81.60
    +0.70 (+0.87%)
     
  • Bitcoin CAD

    85,158.46
    +722.55 (+0.86%)
     
  • CMC Crypto 200

    1,295.94
    +29.80 (+2.35%)
     
  • GOLD FUTURES

    2,334.50
    +21.30 (+0.92%)
     
  • RUSSELL 2000

    2,026.54
    +8.42 (+0.42%)
     
  • 10-Yr Bond

    4.2810
    -0.0350 (-0.81%)
     
  • NASDAQ

    17,857.84
    +52.69 (+0.30%)
     
  • VOLATILITY

    12.41
    -0.14 (-1.12%)
     
  • FTSE

    8,215.47
    -9.86 (-0.12%)
     
  • NIKKEI 225

    39,341.54
    -325.53 (-0.82%)
     
  • CAD/EUR

    0.6815
    -0.0016 (-0.23%)
     

Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc.

PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T.

A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.

ADVERTISEMENT

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs and Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G